chrisvoncsefalvay/vaers-outcomes huggingface dataset:
7 days after  my 1st vaccine a severe rash developed on face and neck; both arms covered w/ red sores. I went to dermatologist and given cortisone ointments that helped; symptoms gradually cleared. I didn't associate symptoms with vaccine. since they appeared 8 days later. I assumed it was a psoraisis flare up, as did my dermatologist.  I had the 2nd vaccine 3 weeks later with no adverse effects until 8 days later when the same symptoms occurred but were more severe. My family doctor (not dermatologist) diagnosed an allergic reaction to the covid vaccinations and prescribed prednisone steroid and cortisone creams. My condition gradually improved over the next 9 days, but I still have small red lesions on both arms.
Early am 11/15/02 awoke to terrible itching on hands. Hives were prominent. Before 11:00am, hands were very swollen, 11/15/02 Went to doctor, Got medicine for itching hives. Sunday evening 11/11/1987 went to ER-Excessive pain in shoulders and wrists, Could not move arms, Pain medication given, Checked by physician on Wed 11/20, still signs of swelling, From that time to present have had swelling and pain in joints of both hands, Right  hand has numbness.
A couple of weeks after the vaccine he started complaining  of stomach pain. My best guess is the vaccine caused a flare up of his Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), which caused anxiety.  12/17/2021- he started complaining of tooth pain, intermittent, he pointed to a general area in his mouth. He saw his dentist on 12/30/2021- the preliminary interpretation thru x-ray his adult tooth was an erosion cyst around an adult tooth. Eruption eroding adjacent baby tooth root and irritating or exposing  the nerves. We don't know why and the dentist does not know why.  They did a biopsy.  The biopsy is part of the eruption to see if there is an infection. The treatment was to pull the baby tooth of the eroded tooth. He had surgery to remove it on 01/04/2022. Outpatient, no hospitalization needed. No, he has not recovered from the AE. He is still healing from surgery and was out of school today, 01/05/2022.
Headache; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) and NAUSEA (Nausea) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     The patient's past medical history included Spinal stenosis.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced HEADACHE (Headache) and NAUSEA (Nausea). At the time of the report, HEADACHE (Headache) and NAUSEA (Nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient's medical history was not provided. No relevant concomitant medications were reported. No treatment information was provided.   Reporter did not allow further contact
The patient called our office on 03/02/2021 and stated that he had chills and a fever. He said his fever was 100 degrees F at the time but had been 100.4 degrees F. I advised him to take Tylenol 325 mg 1 tablet up to 3 times a day if needed. He stated he took a Tylenol and that the fever broke at about 3:00 a.m. on 03/03/2021. He stated that the fever lasted less than 24 hours and that he is feeling better now.
This spontaneous report was received from a nurse refers to multiple unspecified patients of unknown age and gender. On an unknown date, the patients were vaccinated with improperly stored doses of GARDASIL (dose, frequency, route of administration and indication were not reported, lot number# L007560 expiration date: 18-JUN-2017, K006960 expiration date: 19-FEB-2017, K007264 expiration date: 02-MAR-2017, K011562 expiration date: 08-APR-2017, K023432 expiration date: 18-JUN-2016). No adverse events were reported. This is one of the several reports received from the same reporter. Additional information has been requested.
Recipient call the employee health office approximately 24 hours after receiving vaccine stating that they had gone in to an emergency department for evaluation of symptoms. symptoms reported include fever, headache, chills, body aches and blurred vision. Recipient reports that ED physician evaluated her and sent her home with instructions to return in 72 hours if symptoms persist or sooner if symptoms worsen.
Received vaccine at 5 weeks 6 days gestation.  That night I had an elevated temperature 99.8. The next day I had pains in my stomach and uterus. 6 days after the vaccine I miscarried.  The estimated date of delivery would have been tge last week of May 2022.
Patient started with a fever 7-8 hours after vaccination on Monday Aug 7, 2023. Maximum temperature was 103.7 3 days after the vaccination, with associated tingling of the arms and headache. The tingling went away with ibuprofen. Fever lasted for 6+ days. He also has been fatigue despite more than adequate sleep. On Friday , the patient started to have diarrhea/loose stool (>6 times a day, maximum 10+), associated with lower belly discomfort.
Area of increased redness, swelling, pain just below inject site. Ordered Benadryl 25 mg Q 4 hrs.
joint pain in her ankles, knuckles and back; joint pain in her ankles, knuckles and back; Joint pain; Aches/Body ache; Fever/Low grade fever; Dehydration; Indigestion/Heartburn; Fatigue/tired; Lip was twitching briefly; Sleeplessness; Nauseous; This is a spontaneous report from a contactable consumer (patient). A 24-years-old female patient received BNT162b2 (Pfizer BioNTech Covid-19 mRNA Vaccine, Solution for injection; Batch/Lot number: EN6208, Expiry date, NDC number, UPC number was not reported), via an unspecified route of administration on 13Mar2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On Mar2021, patient experienced joint pain, aches/body ache, fever/low grade fever, dehydration, indigestion like heartburn, and fatigue/pretty tired for a week, sleeplessness, nauseous after receiving her vaccine dose. On Mar2021, patient lip was twitching briefly after receiving the vaccine dose, Patient stated that most of her symptoms went away 1 week after receiving the dose. On 28Mar2021, patient stated that her joint pain returned and describes it as mild and sporadic joint pain in her ankles, knuckles and back, like patient have not had to take any medicine or anything for it but patient do notice that she had some joint pain (was fine and then this past Sunday patient started feeling like joint pain). Patient was supposed to get her second dose of the vaccine 03Apr2021. Patient wanted to know if these side effects had been reported and wanted to know if Pfizer had data on individuals who had severe allergic reactions and did, they had them mostly after the first or the second dose. The outcome of joint pain in her ankles, knuckles and back was not recovered and recovered for rest of the events on Mar2021.
This case was reported by a other health professional via call center representative and described the occurrence of paralysis in a adult female patient who received Influenza quadrivalent vaccine unspecified. On an unknown date, the patient received Influenza quadrivalent vaccine unspecified. On an unknown date, less than a year after receiving Influenza quadrivalent vaccine unspecified, the patient experienced paralysis (serious criteria GSK medically significant), arthritis, eczema and allergic reaction. On an unknown date, the outcome of the paralysis and arthritis were recovered/resolved and the outcome of the eczema was unchanged and the outcome of the allergic reaction was unknown. It was unknown if the reporter considered the paralysis, arthritis, eczema and allergic reaction to be related to Influenza quadrivalent vaccine unspecified. Additional details were reported as follows: The healthcare professional reported that the patient had an allergic reaction to one of GSK flu vaccines in 2013. The patient experienced arthritis, paralyzed from neck up immediately after the vaccination. These two adverse events subsided a few days later. The patient also experienced eczema which the patient still experiences over 3 years later at the time of reporting. The patient had a physician visits a few days after receiving the flu vaccine. The healthcare professional did not have any additional information as far as lot number etc. The healthcare professional has no additional information on physician visits etc. The healthcare professional was reaching out to receive ingredient lists for our flu vaccines because the patient was receiving the shingles and pneumonia vaccine and wanted to know if they had similar ingredients.
Patient originally Covid + on 10/06. Tested positive again on 10/14/2021. Patient fully vaccinated with Pfizer. 1st dose 04/21/2021 and 2nd dose on 05/12/2021.  Per HCP: Patient is 49-year-old female with past medical history significant for cardiomyopathy, atrial fibrillation on Eliquis, diabetes mellitus, hypertension, hyperlipidemia presented to the ER with complaints of some chest tightness and feeling out of breath and some lightheadedness. Patient tells me that she was recently diagnosed with COVID-19 infection on 10/6/2021 and she has not been feeling well since then. She said that she has received antibody infusion at a HCF past Tuesday as recommended by her PCP. Although her chest tightness 10 shortness of breath got worsened she said her shortness of breath is more when she exerts and walks. Patient already has been vaccinated with 2 doses of either vaccine in May 2021. Patient also has some coughing and phlegm production. On my evaluation also she has some chest discomfort and she said it is more with the coughing. She denies any chills although she has been having fevers on and off. Patient also is complaining of having diarrhea she denies any abdominal pointer she said she has some nausea here and there no vomiting on further evaluation in the ER her chest x-ray showed patchy opacities throughout the lungs compatible with COVID-19 pneumonia she did not have any leukocytosis she was found to be afebrile her troponin x2 were negative. She had mild hyponatremia with sodium of 130. Patient initially had some hypoxemia although it was resolved on my evaluation patient was maintaining normal saturations on room air
1ST ROUND OF VACCINE 8/15/08: 12 HOURS LATER LOW GRADE FEVER, HEADACHE, SWELLING OF TAILBONE, SEVERE NAUSEA AND DIARRHEA, JOINT PAIN, NOT ABLE TO MOVE FROM BED                                 2ND ROUND OF VACCINE 8/18/08: 8-10 HOURS LATER FEVER, JOINT PAIN, CONTINUATION OF NAUSEA AND DIARRHEA, SEVERE EXHAUSTION, AND SLIGHT RASH    3RD ROUND OF VACCINE 8/22/08: 2-4 HOURS WIDESPREAD RASH SEVERE ITCHING, FATIQUE, NAUSEA AND DIARRHEA, JOINT AND MUSCLE PAIN, THROAT PAIN 4TH ROUND OF VACCINE 8/29/08: 8 HRS AFTER VACCINE MILD RASH, SEVERE JOINT PAIN, CHEST PAIN, NAUSEA AND DIARRHEA, SEVERE FATIQUE (BENADRYL ADMINISTERED BEFORE INJECTION AND EVERY 4 HOURS FOLLOWING
Information has been received from a health professional concerning a 65 year old male with an allergy to sulfa drugs who on 27-DEC-2006 was vaccinated with a 0.1 ml dose of Pneumovax 23 (lot # 655288/1174F).  The Pneumovax 23 vaccine was administered intradermally into the right forearm by error.  Concomitant vaccination on 27-DEC-2006 included a first intradermal dose of PPD (manufacturer unknown) (lot # 33746).  The patient developed redness (2X2 inches) at the injection site but no pain or swelling was reported.  Ice was applied and the arm was checked on 29-DEC-2006 and the redness was gone and the patient recovered.  Additional information is not expected.
Pt recvd Engerix-B on JUN90, SEP90, & JAN91 & it was determined that the pt was a non-responder; tx additional Engerix-B dose;
This spontaneous report as received from a certified medical assistant refers to unspecified number of patients of unknown ages and genders who on unknown dates were vaccinated with an improperly stored doses of VARIVAX (Merck) (dose, lot#, expiration date and route were not reported). No adverse effect reported. It was unknown if the patients sought medical attention. Additional information has been requested.
rash 10-12 vesicular lesions on back, abd, legs day 1 or 2 of illness;
Information has been received from a 71 year old female with cancer, a reaction to dronabinol (MARINOL), and a history of epstein-barr virus infection who on 21-AUG-2006 was vaccinated with a dose of PNEUMOVAX 23.  Concomitant therapy included levofloxacin (LEVAQUIN) and an unspecified antineoplastic.  On approximately 30-AUG-2006, the patient experienced vomiting, nausea, weakness, muscle ache, clogged sinuses and sneezing.  The patient did not seek medical attention for her experience.  At the time of this report, the patient had not recovered.  No further information is available.
pt recv vax 16OCT95&17OCT95 devel a tender&sl enlarged lt supraclavicular lymph node;pt eval by MD;pt reevaluated 24OCT95&event has resolved;
COVID VAccine Breakthrough Case  J&J Dose 10/28/21 (1822809) COVID Positive sometime Nov 2021  12/4/21: 64-year-old female with PMH of recent COVID-19 infection and right pulmonary embolism diagnosed at a HCF, chronic hypoxic respiratory failure on 2 L, COPD, possible lung cancer follows up with Dr., depression, who was discharged from the hospital on December 2, 2021 after being treated for pneumonia with moderate loculated right pleural effusion, and COPD exacerbation.  She presented to ER again with a complaint of sudden onset severe right-sided sharp CP that is constant, worsens with breathing.  That is the only new symptom since discharge, otherwise denied any other complaints.  Patient is an ex-smoker, denies alcohol use, no recreational drug use.   During last admission pulmonology were consulted, patient received treatment for COPD exacerbation including steroids in nebulizer treatments.  Oxygen level were about baseline around 2 L, she finished Levaquin for pneumonia. Pulmonology were consulted in thought effusion is minimal to be aspirated.  Right lower lung had masslike lesions but plan was to have her follow-up with her oncologist for possible PET scan.   In ED, oxygen 5 L by nasal cannula.  No fever, no significant change in lab work including chronic leukopenia.  Due to sudden onset right sided chest pain and elevated D-dimer CT angiogram of the chest was ordered however does official read is up yet.  12/10/21: Patient was admited and was given COVID 19 treatment initially with remdesivir and decadron. Given her COVID positiivty status in October, it is likely the positive PCR is a reflection of recent COVID infection instead of a true acute new re-infection. She was given O2 supplement and her requirement stays around her baseline needs. Pt is up ad lib in room. The initial plan was to have her go back to a facility however insurance denied coverage despite the peer to peer discussion. She underwent O2 walk test and needs 3L with rest and 5L with activity. She is discharged home to complete a few more days of PO steroids. She is discharged in hemodynamically stable conditions. Total time spent on d/c 40 min
No additional AE.; Agency reporting a 10 year old patient received her 2nd dose of GARDASIL 9 too early. The patient received her 1st dose on 20OCT2022 and she received her 2nd dose on 26DEC2022. No additional clarifying statements or details were provided. No additional; This spontaneous report as received from a n unspecified reported mentioned as agency, also reported as Office Manager) refers to a 10 year old patient, gender unspecifed There was no information about the patient's medical history, concurrent conditions or concomitant medication.  On 02-OCT-2022 the patient was vaccinated with a first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9)prefilled syringe, dose: 0.5 milliliter,  lot # 1775827, expiration date: 27-JUN-2024 for prophylaxis (route of administration, and anatomical location were not reported).    The patient received her second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9)prefilled syringe, dose: 0.5 milliliter,  lot # 1775827, expiration date: 27-JUN-2024 for prophylaxis (route of administration, and anatomical location were not reported),  too early on 26-DEC-2022 (Inappropriate schedule of product administration). No additional adverse event. No PQC was reported.
Information has been received from a medical assistant concerning a 26 year old female nursing student who on "25-MAY-2007" was vaccinated with a dose of RECOMBIVAX HB. Subsequently, on "24-MAY-2007" the patient developed a rash all over her body. Unspecified medical attention was sought. Subsequently, on an unspecified date the patient recovered. No other information was provided. There was no product quality complaint involved. Additional information has been requested.
This spontaneous report was received from an office manager and refers to an unspecified number of patients of unknown age and gender. Information on the patients' concurrent conditions, medical history or concomitant therapy was not reported. The office manager reported that the patients received unspecified doses of PEDVAXHIB (lot # M010439 with expiration date: 08-DEC-2018, lot# M014927 with expiration date: 18-FEB-2019, lot# M025193 with expiration date: 21-MAR-2019 and lot# M001813 with expiration date: 14-OCT-2018) that were improperly stored (freezer: temperature of 31F for 5 hours; refrigerator: temperature of 54F for 7 hours; there was a data logger in combination with manual monitoring system). Route of administration was not reported. Vaccinations occurred between 15-SEP-2016 and 16-SEP-2016. No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
This spontaneous report was received from a pharmacist regarding a patient of unknown demographics. On 06-JAN-2014 the patient was vaccinated with ZOSTAVAX (expiry date: 28-SEP-2013), dose: 0.65 ml, subcutaneous. On 06-JAN-2013 the pharmacist reported that patient was administered expired dose of ZOSTAVAX. On an unknown date the patient experienced administered expired dose. She stated that the carton expiration date is: 21-JUN-2014 but that on the vial of ZOSTAVAX the expiration date was: 28-SEP-2013. She stated that the carton was unopened when she received it. No adverse effects reported. There was a product quality complaint involved. The outcome of the medication error was unknown. Additional information has been requested.
Confusion; Memory issues; Fatigue; Headache; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received  first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EP7533) via an unspecified route of administration in the left arm on 03Apr2021 at 14:45 (at the age of 51-years-old), and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: ER8735) via an unspecified route of administration in the left arm on 24Apr2021 at 14:30 (at the age of 51-years-old); both as a single dose for COVID-19 immunisation. Medical history included allergies to eggs, peanuts, wheat, soy, corn, tomatoes and peppers. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified multivitamin, paracetamol (TYLENOL), ibuprofen (MANUFACTURER UNKNOWN) and bupropion hydrochloride (WELLBUTRIN SR); all for unspecified indication from unknown date and unknown if ongoing. The patient previously received morphine (MANUFACTURER UNKNOWN), tramadol (MANUFACTURER UNKNOWN) and ciprofloxacin (MANUFACTURER UNKNOWN); all for unspecified indication from unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Apr2021 at 12:00, the patient experienced confusion, memory issues, fatigue and headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of confusion, memory issues, fatigue and headache was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A and 011L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In February 2021, the patient experienced PYREXIA (fever). At the time of the report, PYREXIA (fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In February 2021, Body temperature: 97 (normal) in the morning it is 97 and 100 (High) high. On 19-Jun-2021, SARS-CoV-2 antibody test: positive (Positive) Reactive positive for Anti-SARS-COV-2 IgG antibodies. On 19-Jun-2021, SARS-CoV-2 test: negative (Negative) first dry blood spot test Reactive # of 8.52 with <1.41 index.. On 08-Sep-2021, SARS-CoV-2 antibody test: positive (Positive) Reactive positive for Anti-SARS-COV-2 IgG antibodies. On 08-Sep-2021, SARS-CoV-2 test: negative (Negative) dry blood spot test showed a Reactive # of 2.93 with <1.41 index..         Concomitant medications were not provided.  Treatment information was not provided.  After the second one patient had a fever, normally in the morning  fever is 97. something did not remember how high was when took it but it went to 100°F and stopped taking it after that was perfectly fine. The test results show with the first dry blood spot test Reactive # of 8.52 with <1.41 index on June.19. Patient went for the 2nd antibody test and the dry blood spot test showed a Reactive # of 2.93 with <1.41 index .on Sept.8.   This case was linked to MOD-2021-335496 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 02-Oct-2021: FU received on 04-OCT-2021. Lab results updated.
Arthralgia, Fever, NauseaVomiting, Fatigue Narrative: Aches bad all over
Moderma Covid 19 Vaccine EUA On the 15th, I had headache, body aches, low grade fever.  I took Ibuprofen every 4 times that day.  The headache would subside for a short time and then return. On the 16th, body aches continued.  Headache was not as bad but I could tell my head wasn't clear yet.   I was fatigued and rested a lot.  I took Ibuprofen with my normal bedtime medicines. On the 17th, I got up feeling well.
Redness and swelling at injection site, then a red itchy patch below the injection site and above the injection site.   The following morning, 5/19/19 the right side of her face had a red itch rash.     Treated applying heat to the areas on arm, no treatment on the face
COVID 19; COVID 19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41-year-old male patient received BNT162b2 (BNT162B2), in May2022 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". Therapeutic measures were taken as a result of drug ineffective, covid-19. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.